Moomoo AI 已提取核心信息
Eli Lilly and Company (NYSE: LLY), a global pharmaceutical company, reported a strong financial performance for the fourth quarter of 2023, with a 28% increase in revenue compared to the same period in 2022. The company's revenue for Q4 2023 was $9.35 billion, driven by higher realized prices and volume growth. New Products revenue, led by Mounjaro and Zepbound, grew to $2.49 billion, while Growth Products revenue, led by Verzenio and Jardiance, increased by 9% to $5.27 billion. The company's EPS also saw a significant increase, with reported EPS growing 13% to $2.42 and non-GAAP EPS increasing 19% to $2.49. Eli Lilly provided guidance for 2024, projecting revenue in the range of $40.4 billion to $41.6 billion and EPS between $11.80 and $12.30 on a reported basis, and $12.20 to $12.70 on a non-GAAP basis. The...Show More
Eli Lilly and Company (NYSE: LLY), a global pharmaceutical company, reported a strong financial performance for the fourth quarter of 2023, with a 28% increase in revenue compared to the same period in 2022. The company's revenue for Q4 2023 was $9.35 billion, driven by higher realized prices and volume growth. New Products revenue, led by Mounjaro and Zepbound, grew to $2.49 billion, while Growth Products revenue, led by Verzenio and Jardiance, increased by 9% to $5.27 billion. The company's EPS also saw a significant increase, with reported EPS growing 13% to $2.42 and non-GAAP EPS increasing 19% to $2.49. Eli Lilly provided guidance for 2024, projecting revenue in the range of $40.4 billion to $41.6 billion and EPS between $11.80 and $12.30 on a reported basis, and $12.20 to $12.70 on a non-GAAP basis. The company's financial results were bolstered by FDA approvals of Zepbound for obesity and Jaypirca for chronic lymphocytic leukemia, as well as positive results from a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH). Additionally, Eli Lilly completed acquisitions of POINT Biopharma Global Inc. and Mablink Biosciences SAS, and announced a 15% annual increase in its quarterly dividend.
全球制药公司礼来公司（纽约证券交易所代码：LLY）报告了2023年第四季度的强劲财务表现，收入与2022年同期相比增长了28％。该公司2023年第四季度的收入为93.5亿美元，这得益于更高的已实现价格和销量增长。以Mounjaro和Zepbound为首的新产品收入增长至24.9亿美元，而以Verzenio和Jardiance为首的成长产品收入增长了9％，达到52.7亿美元。该公司的每股收益也大幅增长，报告的每股收益增长13％，至2.42美元，非公认会计准则每股收益增长19％，至2.49美元。礼来公司提供了2024年的指导方针，预计收入在404亿美元至416亿美元之间，按报告计算，每股收益在11...展开全部
全球制药公司礼来公司（纽约证券交易所代码：LLY）报告了2023年第四季度的强劲财务表现，收入与2022年同期相比增长了28％。该公司2023年第四季度的收入为93.5亿美元，这得益于更高的已实现价格和销量增长。以Mounjaro和Zepbound为首的新产品收入增长至24.9亿美元，而以Verzenio和Jardiance为首的成长产品收入增长了9％，达到52.7亿美元。该公司的每股收益也大幅增长，报告的每股收益增长13％，至2.42美元，非公认会计准则每股收益增长19％，至2.49美元。礼来公司提供了2024年的指导方针，预计收入在404亿美元至416亿美元之间，按报告计算，每股收益在11.80美元至12.30美元之间，按非公认会计准则计算，收入在12.20美元至12.70美元之间。该公司的财务业绩得益于美国食品药品管理局批准Zepbound用于肥胖症和Jaypirca用于治疗慢性淋巴细胞白血病，以及一项针对非酒精性脂肪肝炎（NASH）成人替塞帕肽的2期研究的积极结果。此外，礼来公司完成了对POINT Biopharma Global Inc.和Mablink Biosciences SAS的收购，并宣布其季度股息每年增长15％。
有用
没用